What a 26% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
The archive — 2025
Page 25 of 68 of this archive, newest first.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a CPC orforglipron lot at 95.3%, against 92.5% on the certificate
The result is unremarkable. What the report omits is not.
Chain of custody, and where it begins
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
Four millimetres is enough, and the data says so
The insulin injection-technique literature is large, well conducted and directly transferable on questions of depth and tissue. We say where it stops transferring.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Changsha export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Nigeria declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a laboratory knows about the material it receives
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
How a claim degrades between the bench and the listing
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
Why your laboratory interval differs from the one in the textbook
A twelve-analyte panel in a perfectly healthy person has roughly even odds of producing at least one flagged result.
What changed at QSC in August, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Medutest result on a Suzhou semaglutide lot lands 4.3 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
From the floor in Guangzhou: 22 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the GLP-1 receptor actually does when orforglipron binds it
The class is described as though every molecule in it did the same thing. At the receptor, they demonstrably do not.
STEP 8 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Canada declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
Norway pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Reading the semaglutide composition data without the press release
A substudy powered to describe a mean is not a substudy powered to detect a clinically meaningful individual change.
Why Medutest can tell you the mass is right and not that the sequence is
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
Medutest result on a Shanghai mazdutide lot lands 1.2 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
What a 24% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
A shortage listing ends. 10 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
When a symptom is information and when it is noise
Nausea and gastric delay attenuate over weeks at an unchanged dose. That single physiological fact is the entire justification for holding.
The lowest effective dose is a real concept with almost no data behind it
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
SURMOUNT-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.